Ketamine is everywhere. Is that a good thing?

The FDA approval process was not as transparent as it seems.

In March 2019 the FDA approved ketamine, under the trade name Spravato (esketamine), for clinical use in treatment-resistant depression therapy. Alongside racemic ketamine, which is commonly used in ketamine infusion therapy, ketamine is the first hallucinogen approved for therapeutic usage in the United States.

Technically, ketamine is not a psychedelic…